Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

Autor: Caroline J. Coats, Ahmad Masri, Michael E. Nassif, Roberto Barriales‐Villa, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Hans‐Dirk Düngen, Pablo Garcia‐Pavia, Albert A. Hagège, James L. Januzzi, Matthew M. Y. Lee, Gregory D. Lewis, Chang‐Sheng Ma, Martin S. Maron, Zi Michael Miao, Michelle Michels, Iacopo Olivotto, Artur Oreziak, Anjali T. Owens, John A. Spertus, Scott D. Solomon, Jacob Tfelt‐Hansen, Marion van Sinttruije, Josef Veselka, Hugh Watkins, Daniel L. Jacoby, Polina German, Stephen B. Heitner, Stuart Kupfer, Justin D. Lutz, Fady I. Malik, Lisa Meng, Amy Wohltman, Theodore P. Abraham

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 15 (2024)

Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in

Externí odkaz: https://doaj.org/article/ecd7f5b3949f4a8ca276c42cd7292a3f

Sudden Cardiac Death Risk over Time in HCM Patients with Implantable Cardioverter-Defibrillator

Autor: Mariusz, Klopotowski, Krzysztof, Kukula, Jacek, Jamiolkowski, Artur, Oreziak, Maciej, Dabrowski, Zbigniew, Chmielak, Adam, Witkowski

Publikováno v: Journal of Clinical Medicine; Volume 11; Issue 6; Pages: 1633

Background: In patients with HCM at high risk of SCD, an ICD should be considered as a standard of care. Current risk approximation algorithms recommended by ESC 2014 criteria indicate that SCD risk is not stable. The aim of the study was to investig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91155baa80c66a3119f9621312c91ec
https://doi.org/10.3390/jcm11061633

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, Neal K Lakdawala, Matthew T Wheeler, Anjali Owens, Milos Kubanek, Wojciech Wojakowski, Morten K Jensen, Juan Gimeno-Blanes, Kia Afshar, Jonathan Myers, Sheila M Hegde, Scott D Solomon, Amy J Sehnert, David Zhang, Wanying Li, Mondira Bhattacharya, Jay M Edelberg, Cynthia Burstein Waldman, Steven J Lester, Andrew Wang, Carolyn Y Ho, Daniel Jacoby, Jozef Bartunek, Antoine Bondue, Emeline Van Craenenbroeck, David Zemanek, Morten Jensen, Jens Mogensen, Jens Jakob Thune, Philippe Charron, Albert Hagege, Olivier Lairez, Jean-Noël Trochu, Christoph Axthelm, Hans-Dirk Duengen, Norbert Frey, Veselin Mitrovic, Michael Preusch, Jeanette Schulz-Menger, Tim Seidler, Michael Arad, Majdi Halabi, Amos Katz, Daniel Monakier, Offir Paz, Samuel Viskin, Donna Zwas, Hans Peter Brunner-La Rocca, Michelle Michels, Dariusz Dudek, Zofia Oko-Sarnowska, Nuno Cardim, Helder Pereira, Pablo García Pavia, Juan Gimeno Blanes, Rafael Hidalgo Urbano, Luis Miguel Rincón Diaz, Perry Elliott, Zaheer Yousef, Theodore Abraham, Paulino Alvarez, Richard Bach, Richard Becker, Lubna Choudhury, David Fermin, John Jefferies, Christopher Kramer, Neal Lakdawala, Steven Lester, Ali Marian, Mathew Maurer, Sherif Nagueh, David Owens, Florian Rader, Mark Sherrid, Jamshid Shirani, John Symanski, Aslan Turer, Omar Wever-Pinzon, Matthew Wheeler, Timothy Wong, Mohamad Yamani

Publikováno v: DDFV: Repositorio Institucional de la Universidad Francisco de Vitoria
Universidad Francisco de Vitoria
The Lancet
The Lancet, Elsevier, 2020, 396 (10253), pp.759-769. ⟨10.1016/S0140-6736(20)31792-X⟩
Lancet, 396(10253), 759-769. Elsevier Science
DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
instname
Olivotto, I, Oreziak, A, Barriales-Villa, R, Abraham, T P, Masri, A, García Pavia, P, Saberi, S, Lakdawala, N K, Wheeler, M T, Owens, A, Kubanek, M, Wojakowski, W, Jensen, M K, Gimeno-Blanes, J, Afshar, K, Myers, J, Hegde, S M, Solomon, S D, Sehnert, A J, Zhang, D, Li, W, Bhattacharya, M, Edelberg, J M, Waldman, C B, Lester, S J, Wang, A, Ho, C Y, Jacoby, D & EXPLORER-HCM 2020, ' Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 396, no. 10253, pp. 759-769 . https://doi.org/10.1016/S0140-6736(20)31792-X

Background: Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7751fccc2de1b5093dee54ed23cc2cd
http://hdl.handle.net/10641/2370

[Heart wall perforation after implantation of pacemaker - it happens]

Autor: Artur, Oreziak

Publikováno v: Kardiologia polska. 68(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7309ff8cf6702a749c6626b47f3ac718
https://pubmed.ncbi.nlm.nih.gov/20411465

[Inappropriate therapy of an implantable cardioverter-defibrillator--is it always an undesired event?]

Autor: Artur, Oreziak, Andrzej, Przybylski

Publikováno v: Kardiologia polska. 67(8)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cc2f166ddfeb6a2d536e71dfac6825ed
https://pubmed.ncbi.nlm.nih.gov/19784895